Provided by Tiger Fintech (Singapore) Pte. Ltd.

Entrada Therapeutics, Inc.

9.13
+0.19002.13%
Pre-market: 8.61-0.5200-5.70%07:00 EDT
Volume:127.38K
Turnover:1.16M
Market Cap:343.24M
PE:5.43
High:9.27
Open:8.77
Low:8.69
Close:8.94
Loading ...

Azenta Announces the Election of Dipal Doshi to its Board of Directors

PR Newswire
·
31 Jan

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Simply Wall St.
·
26 Jan

Here's Why Encompass Health is a Smart Addition to Your Portfolio

Zacks
·
31 Dec 2024

Best Momentum Stocks to Buy for December 30th

Zacks
·
30 Dec 2024

New Strong Buy Stocks for December 30th

Zacks
·
30 Dec 2024

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating

TIPRANKS
·
06 Dec 2024

Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating

MT Newswires Live
·
06 Nov 2024

Entrada Therapeutics, Inc. : Oppenheimer Raises Target Price to $28 From $25

THOMSON REUTERS
·
06 Nov 2024

Entrada Therapeutics price target raised to $20 from $18 at H.C. Wainwright

TIPRANKS
·
06 Nov 2024

Entrada Therapeutics’ Q3 2024 Financial Highlights

TIPRANKS
·
06 Nov 2024

TD Cowen Sticks to Its Buy Rating for Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
05 Nov 2024

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
05 Nov 2024

Entrada Therapeutics Says Cash Runway Expected Into 2027 With $449M In Cash, Cash Equivalents And Marketable Securities As Of September 30, 2024

Benzinga
·
05 Nov 2024

Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate

Benzinga
·
05 Nov 2024

Entrada Therapeutics Inc: Cash Runway Expected Into 2027

THOMSON REUTERS
·
05 Nov 2024

Entrada Therapeutics, Inc. Q3 Income From Operations USD -21.658 Million

THOMSON REUTERS
·
05 Nov 2024

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire
·
05 Nov 2024